Barclays analyst Emily Field lowered the firm’s price target on Sanofi (SNY) to EUR 115 from EUR 125 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
- Sanofi’s Phase 3 MS Study: Tolebrutinib vs. Teriflunomide
- Sanofi’s Tolebrutinib Study Completion: A Potential Game-Changer for NRSPMS Treatment
- Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
- Sanofi’s Observational Study on Teplizumab: Real-World Insights for Type 1 Diabetes